Cencora, Inc 8-K, filed Nov 4, 2026
Cencora, Inc. (COR)
8-K
2026-11-04
For: 2026-11-04
View Original
Added on
November 04, 2026
About this 8-K
Cencora, Inc filed this 8-K on November 4, 2026.
Cencora recently completed an operating-model restructuring and will begin reporting in a new structure in the first quarter of fiscal 2027: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. AI summary
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_________________________________
FORM 8-K
_________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2026
_________________________________
(Exact name of registrant as specified in its charter)
_________________________________
Commission File Number: 1-16671
| (State or other jurisdiction of | (I.R.S. Employer | |||||||||||||
| incorporation or organization) | Identification No.) | |||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
(610 ) 727-7000
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | |||||||||
| (NYSE) | |||||||||||
| (NYSE) | |||||||||||
| (NYSE) | |||||||||||
_________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 7.01. Regulation FD Disclosure.
New Reporting Structure
In order to advance its growth priorities, Cencora recently completed a restructuring of its operating model intended to strengthen execution and improve visibility. As a result of this restructuring, the Company has reorganized all business components within the U.S. Healthcare Solutions and International Healthcare Solutions reportable segments. Beginning in the first quarter of fiscal 2027, the Company’s reporting structure will be comprised of Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. The Pharmaceutical Distribution and Services reportable segment will consist of U.S. and international wholesale pharmaceutical distribution and related services that support health systems, retail pharmacies, and alternate sites of care. The Specialty Pharmaceutical and Provider Services reportable segment will consist of specialty distribution services to physician practices, management services organizations, World Courier and third-party logistics (3PL) services, Innomar and strategic components of PharmaLex. Other, which is not considered a reportable segment, will continue to consist of businesses for which the Company is exploring strategic alternatives, including MWI Animal Health, Profarma, and the other components of PharmaLex.
In the attached Exhibit 99.1, which is incorporated herein by reference, the Company is voluntarily furnishing a supplemental disclosure of unaudited revised summary reportable segment information for each of the quarters of fiscal 2026 and 2025 and the fiscal years ended September 30, 2026 and 2025 under the reporting structure that will be utilized in fiscal 2027 to assist investors in analyzing the changes to its reporting structure.
The information in this Current Report, including the exhibit attached hereto as Exhibit 99.1, is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | ||||
| 99.1 | |||||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Cencora, Inc. | |||||||||||
| Date: | By: | /s/ Eva C. Boratto | |||||||||
| Name: | Eva C. Boratto | ||||||||||
| Title: | Executive Vice President & Chief Financial Officer | ||||||||||
Exhibit 99.1
CENCORA, INC.
SUMMARY REPORTABLE SEGMENT INFORMATION
(in thousands)
(unaudited)
The following illustrates revised reportable segment revenue information for the periods indicated:
| Fiscal Year Ended September 30, 2026 | ||||||||||||||||||||||||||||||||
| Revenue | First Quarter | Second Quarter | Third Quarter | Fourth Quarter | Fiscal Year | |||||||||||||||||||||||||||
| (As Revised) | (As Revised) | (As Revised) | (As Revised) | (As Revised) | ||||||||||||||||||||||||||||
| Pharmaceutical Distribution and Services | $ | 72,969,277 | $ | 66,108,390 | $ | 71,164,265 | $ | 74,242,224 | $ | 284,484,156 | ||||||||||||||||||||||
| Specialty Pharmaceutical and Provider Services | 11,098,508 | 10,471,417 | 11,645,430 | 12,175,177 | 45,390,532 | |||||||||||||||||||||||||||
| Other | 2,128,947 | 2,055,571 | 2,253,330 | 2,302,073 | 8,739,921 | |||||||||||||||||||||||||||
| Intersegment eliminations | (264,716) | (279,462) | (308,188) | (364,944) | (1,217,310) | |||||||||||||||||||||||||||
| Total revenue | $ | 85,932,016 | $ | 78,355,916 | $ | 84,754,837 | $ | 88,354,530 | $ | 337,397,299 | ||||||||||||||||||||||
| Fiscal Year Ended September 30, 2025 | ||||||||||||||||||||||||||||||||
| Revenue | First Quarter | Second Quarter | Third Quarter | Fourth Quarter | Fiscal Year | |||||||||||||||||||||||||||
| (As Revised) | (As Revised) | (As Revised) | (As Revised) | (As Revised) | ||||||||||||||||||||||||||||
| Pharmaceutical Distribution and Services | $ | 69,441,734 | $ | 63,350,601 | $ | 67,700,658 | $ | 71,352,299 | $ | 271,845,292 | ||||||||||||||||||||||
| Specialty Pharmaceutical and Provider Services | 10,490,286 | 10,418,900 | 11,136,471 | 10,542,389 | 42,588,046 | |||||||||||||||||||||||||||
| Other | 2,002,455 | 1,956,407 | 2,107,464 | 2,091,507 | 8,157,833 | |||||||||||||||||||||||||||
| Intersegment eliminations | (447,415) | (272,235) | (281,061) | (257,641) | (1,258,352) | |||||||||||||||||||||||||||
| Total revenue | $ | 81,487,060 | $ | 75,453,673 | $ | 80,663,532 | $ | 83,728,554 | $ | 321,332,819 | ||||||||||||||||||||||
CENCORA, INC.
SUMMARY REPORTABLE SEGMENT INFORMATION
(in thousands)
(unaudited)
The following illustrates revised reportable segment operating income and margin information for the periods indicated:
| Fiscal Year Ended September 30, 2026 | ||||||||||||||||||||||||||||||||
| Operating income | First Quarter | Second Quarter | Third Quarter | Fourth Quarter | Fiscal Year | |||||||||||||||||||||||||||
| (As Revised) | (As Revised) | (As Revised) | (As Revised) | (As Revised) | ||||||||||||||||||||||||||||
| Pharmaceutical Distribution and Services | $ | 606,904 | $ | 774,786 | $ | 664,122 | $ | 690,546 | $ | 2,736,358 | ||||||||||||||||||||||
| Specialty Pharmaceutical and Provider Services | 366,582 | 399,311 | 467,908 | 459,221 | 1,693,022 | |||||||||||||||||||||||||||
| Other | 91,417 | 91,633 | 108,736 | 101,075 | 392,861 | |||||||||||||||||||||||||||
| Intersegment eliminations | (2,189) | (2,381) | (2,680) | (1,944) | (9,194) | |||||||||||||||||||||||||||
| Total segment operating income | $ | 1,062,714 | $ | 1,263,349 | $ | 1,238,086 | $ | 1,248,898 | $ | 4,813,047 | ||||||||||||||||||||||
| Percentages of revenue: | ||||||||||||||||||||||||||||||||
| Pharmaceutical Distribution and Services | ||||||||||||||||||||||||||||||||
| Gross profit | 2.26% | 2.70% | 2.39% | 2.31% | 2.41% | |||||||||||||||||||||||||||
| Operating expenses | 1.43% | 1.52% | 1.45% | 1.38% | 1.45% | |||||||||||||||||||||||||||
| Operating income | 0.83% | 1.17% | 0.93% | 0.93% | 0.96% | |||||||||||||||||||||||||||
| Specialty Pharmaceutical and Provider Services | ||||||||||||||||||||||||||||||||
| Gross profit | 9.21% | 12.27% | 12.89% | 12.58% | 11.76% | |||||||||||||||||||||||||||
| Operating expenses | 5.91% | 8.45% | 8.88% | 8.81% | 8.03% | |||||||||||||||||||||||||||
| Operating income | 3.30% | 3.81% | 4.02% | 3.77% | 3.73% | |||||||||||||||||||||||||||
| Other | ||||||||||||||||||||||||||||||||
| Gross profit | 15.24% | 15.16% | 14.58% | 14.30% | 14.81% | |||||||||||||||||||||||||||
| Operating expenses | 10.95% | 10.70% | 9.76% | 9.91% | 10.31% | |||||||||||||||||||||||||||
| Operating income | 4.29% | 4.46% | 4.83% | 4.39% | 4.50% | |||||||||||||||||||||||||||
CENCORA, INC.
SUMMARY REPORTABLE SEGMENT INFORMATION
(in thousands)
(unaudited)
| Fiscal Year Ended September 30, 2025 | ||||||||||||||||||||||||||||||||
| Operating income | First Quarter | Second Quarter | Third Quarter | Fourth Quarter | Fiscal Year | |||||||||||||||||||||||||||
| (As Revised) | (As Revised) | (As Revised) | (As Revised) | (As Revised) | ||||||||||||||||||||||||||||
| Pharmaceutical Distribution and Services | $ | 569,446 | $ | 725,639 | $ | 590,995 | $ | 614,651 | $ | 2,500,731 | ||||||||||||||||||||||
| Specialty Pharmaceutical and Provider Services | 282,531 | 373,741 | 380,246 | 333,989 | 1,370,507 | |||||||||||||||||||||||||||
| Other | 97,329 | 92,851 | 87,104 | 74,429 | 351,713 | |||||||||||||||||||||||||||
| Intersegment eliminations | 2 | 33 | (14) | 1 | 22 | |||||||||||||||||||||||||||
| Total segment operating income | $ | 949,308 | $ | 1,192,264 | $ | 1,058,331 | $ | 1,023,070 | $ | 4,222,973 | ||||||||||||||||||||||
| Percentages of revenue: | ||||||||||||||||||||||||||||||||
| Pharmaceutical Distribution and Services | ||||||||||||||||||||||||||||||||
| Gross profit | 2.27% | 2.62% | 2.33% | 2.28% | 2.37% | |||||||||||||||||||||||||||
| Operating expenses | 1.45% | 1.47% | 1.46% | 1.42% | 1.45% | |||||||||||||||||||||||||||
| Operating income | 0.82% | 1.15% | 0.87% | 0.86% | 0.92% | |||||||||||||||||||||||||||
| Specialty Pharmaceutical and Provider Services | ||||||||||||||||||||||||||||||||
| Gross profit | 6.14% | 9.01% | 8.67% | 9.23% | 8.27% | |||||||||||||||||||||||||||
| Operating expenses | 3.44% | 5.42% | 5.26% | 6.07% | 5.05% | |||||||||||||||||||||||||||
| Operating income | 2.69% | 3.59% | 3.41% | 3.17% | 3.22% | |||||||||||||||||||||||||||
| Other | ||||||||||||||||||||||||||||||||
| Gross profit | 15.86% | 16.27% | 14.95% | 14.57% | 15.40% | |||||||||||||||||||||||||||
| Operating expenses | 11.00% | 11.53% | 10.82% | 11.01% | 11.08% | |||||||||||||||||||||||||||
| Operating income | 4.86% | 4.75% | 4.13% | 3.56% | 4.31% | |||||||||||||||||||||||||||